JP2015531873A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015531873A5 JP2015531873A5 JP2015531492A JP2015531492A JP2015531873A5 JP 2015531873 A5 JP2015531873 A5 JP 2015531873A5 JP 2015531492 A JP2015531492 A JP 2015531492A JP 2015531492 A JP2015531492 A JP 2015531492A JP 2015531873 A5 JP2015531873 A5 JP 2015531873A5
- Authority
- JP
- Japan
- Prior art keywords
- amount
- subject
- sample
- fgf
- specifically binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 38
- 102000004042 Fibroblast Growth Factor-23 Human genes 0.000 claims 22
- 108090000569 Fibroblast Growth Factor-23 Proteins 0.000 claims 22
- 239000003795 chemical substances by application Substances 0.000 claims 15
- 238000001514 detection method Methods 0.000 claims 15
- 238000003384 imaging method Methods 0.000 claims 13
- 230000000747 cardiac effect Effects 0.000 claims 11
- 101000840577 Homo sapiens Insulin-like growth factor-binding protein 7 Proteins 0.000 claims 7
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 claims 7
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 7
- 206010019280 Heart failures Diseases 0.000 claims 5
- 229930003316 Vitamin D Natural products 0.000 claims 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 5
- 230000007211 cardiovascular event Effects 0.000 claims 5
- 235000019166 vitamin D Nutrition 0.000 claims 5
- 239000011710 vitamin D Substances 0.000 claims 5
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 5
- 229940046008 vitamin d Drugs 0.000 claims 5
- 102400001047 Endostatin Human genes 0.000 claims 4
- 108010079505 Endostatins Proteins 0.000 claims 4
- 238000007435 diagnostic evaluation Methods 0.000 claims 4
- 230000002861 ventricular Effects 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 210000002381 plasma Anatomy 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims 2
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims 2
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000000717 retained effect Effects 0.000 claims 2
- 208000020446 Cardiac disease Diseases 0.000 claims 1
- 102100026632 Mimecan Human genes 0.000 claims 1
- 108091013859 Mimecan Proteins 0.000 claims 1
- 102400001263 NT-proBNP Human genes 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 238000004364 calculation method Methods 0.000 claims 1
- 238000002592 echocardiography Methods 0.000 claims 1
- 238000002595 magnetic resonance imaging Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12184085 | 2012-09-12 | ||
| EP12184085.4 | 2012-09-12 | ||
| PCT/EP2013/056706 WO2014040759A1 (en) | 2012-09-12 | 2013-03-28 | Identification of patients with abnormal fractional shortening |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017220660A Division JP6615848B2 (ja) | 2012-09-12 | 2017-11-16 | 異常な短縮率（ｆｒａｃｔｉｏｎａｌ ｓｈｏｒｔｅｎｉｎｇ）を持つ患者の同定 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015531873A JP2015531873A (ja) | 2015-11-05 |
| JP2015531873A5 true JP2015531873A5 (enExample) | 2016-05-19 |
| JP6247302B2 JP6247302B2 (ja) | 2017-12-13 |
Family
ID=46826365
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015531492A Active JP6247302B2 (ja) | 2012-09-12 | 2013-03-28 | 異常な短縮率（ｆｒａｃｔｉｏｎａｌｓｈｏｒｔｅｎｉｎｇ）を持つ患者の同定 |
| JP2017220660A Active JP6615848B2 (ja) | 2012-09-12 | 2017-11-16 | 異常な短縮率（ｆｒａｃｔｉｏｎａｌ ｓｈｏｒｔｅｎｉｎｇ）を持つ患者の同定 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017220660A Active JP6615848B2 (ja) | 2012-09-12 | 2017-11-16 | 異常な短縮率（ｆｒａｃｔｉｏｎａｌ ｓｈｏｒｔｅｎｉｎｇ）を持つ患者の同定 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20150185230A1 (enExample) |
| EP (3) | EP4075143A1 (enExample) |
| JP (2) | JP6247302B2 (enExample) |
| CN (1) | CN104620111B (enExample) |
| CA (1) | CA2883890C (enExample) |
| ES (2) | ES2680149T3 (enExample) |
| WO (1) | WO2014040759A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103998938B (zh) | 2011-10-17 | 2016-06-15 | 霍夫曼-拉罗奇有限公司 | 风险患者和中风原因的基于肌钙蛋白和bnp的诊断 |
| ES2939018T3 (es) | 2014-03-26 | 2023-04-18 | Hoffmann La Roche | IGFBP7 para diagnosticar una disfunción diastólica |
| EP4300104A3 (en) * | 2014-10-29 | 2024-09-25 | Roche Diagnostics GmbH | Biomarker for risk prediction of mortality |
| CN108139409B (zh) | 2015-10-08 | 2020-07-24 | 豪夫迈·罗氏有限公司 | 当在外科手术之前测量时用于预测aki的风险的igfbp7 |
| WO2017125406A1 (en) * | 2016-01-19 | 2017-07-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting left ventricular remodeling in subjects suffering from hypertension |
| AU2018275236B2 (en) * | 2017-05-30 | 2024-11-07 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I |
| ES2977423T3 (es) | 2017-12-13 | 2024-08-23 | Hoffmann La Roche | Angiopoyetina-2 (Ang-2) circulante y proteína de unión al factor de crecimiento insulínico 7 (IGFBP7) para la predicción de apoplejía |
| JP7024576B2 (ja) * | 2018-04-20 | 2022-02-24 | オムロンヘルスケア株式会社 | 電子血圧計および心不全検出器 |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
| US12322100B2 (en) | 2018-12-11 | 2025-06-03 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity |
| US12400762B2 (en) | 2018-12-11 | 2025-08-26 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy |
| US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
| WO2023175176A1 (en) * | 2022-03-18 | 2023-09-21 | Roche Diagnostics Gmbh | Cmybpc marker combinations for early discrimination of type 2 versus type 1 acute myocardial infarction |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| GB9211686D0 (en) | 1992-06-03 | 1992-07-15 | Medisinsk Innovation A S | Chemical compounds |
| US6709855B1 (en) | 1998-12-18 | 2004-03-23 | Scios, Inc. | Methods for detection and use of differentially expressed genes in disease states |
| JP2004532202A (ja) * | 2001-03-15 | 2004-10-21 | シアオ，ヨング−フー | 生存哺乳動物における臨床的に認められた形態の心臓の病状を治療的に処置する方法 |
| US7632647B2 (en) | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| DE60233301D1 (de) | 2001-05-04 | 2009-09-24 | Biosite Inc | Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs |
| WO2003043487A2 (en) * | 2001-11-19 | 2003-05-30 | Protometrix, Inc. | Method of using a non-antibody protein to detect and measure an analyte |
| JP2005291899A (ja) * | 2004-03-31 | 2005-10-20 | Akira Matsumori | 心疾患の検査法 |
| US8563328B2 (en) * | 2004-07-26 | 2013-10-22 | University Of Louisville Research Foundation, Inc. | Fiber-optic biosensor and biosensing methods |
| US20080027330A1 (en) * | 2006-05-15 | 2008-01-31 | Endothelix, Inc. | Risk assessment method for acute cardiovascular events |
| WO2008060618A2 (en) * | 2006-11-15 | 2008-05-22 | University Of Florida Research Foundation | Use of genetic determinants in cardiovascular risk assessment |
| PL2115477T3 (pl) * | 2007-01-25 | 2015-12-31 | Hoffmann La Roche | Zastosowanie IGFBP-7 do oceny niewydolności serca |
| US8182998B2 (en) * | 2007-04-26 | 2012-05-22 | Genera Istrazivanja D.O.O. | Blood biomarkers for bone fracture and cartilage injury |
| EP2515116A1 (en) | 2007-05-18 | 2012-10-24 | Duke University | Serum biomarkers for the early detection of lung cancer |
| US20110183434A1 (en) * | 2008-01-17 | 2011-07-28 | Myles Wolf | Diagnostic methods and kits using fibroblast growth factor-23 |
| US20120010094A1 (en) * | 2008-11-06 | 2012-01-12 | Musc Foundation For Research Development | Detecting and monitoring left ventricular hypertrophy and congestive heart failure by profiling biomarkers |
| CN102448927A (zh) | 2009-04-01 | 2012-05-09 | 力奇制药公司 | 活性亚甲基基团的二甲基化的方法 |
| CN102422157B (zh) * | 2009-04-27 | 2014-10-29 | 霍夫曼-拉罗奇有限公司 | 内皮抑制素作为心力衰竭标记的应用 |
| CA2769243C (en) | 2009-07-27 | 2017-08-22 | F. Hoffmann-La Roche Ag | Use of mimecan in the assessment of heart failure |
| JP5763098B2 (ja) * | 2009-12-20 | 2015-08-12 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| EP2924439B1 (en) * | 2010-03-26 | 2017-02-01 | MyCartis N.V. | Ltbp2 as a biomarker for predicting or prognosticating mortality |
| US20120142632A1 (en) * | 2010-08-04 | 2012-06-07 | St. Vincent's Institute Of Medical Research | Diagnostic and prognostic assay |
| JP5676763B2 (ja) | 2010-08-26 | 2015-02-25 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 動脈性高血圧症から心不全への初期移行の評価におけるバイオマーカーの使用 |
| WO2012029837A1 (ja) * | 2010-08-31 | 2012-03-08 | 協和メデックス株式会社 | 線維芽細胞増殖因子－２３の測定方法及び測定試薬 |
-
2013
- 2013-03-28 EP EP22161423.3A patent/EP4075143A1/en active Pending
- 2013-03-28 EP EP13713175.1A patent/EP2895866B1/en active Active
- 2013-03-28 JP JP2015531492A patent/JP6247302B2/ja active Active
- 2013-03-28 WO PCT/EP2013/056706 patent/WO2014040759A1/en not_active Ceased
- 2013-03-28 ES ES13713175.1T patent/ES2680149T3/es active Active
- 2013-03-28 EP EP18174585.2A patent/EP3428649B1/en active Active
- 2013-03-28 ES ES18174585T patent/ES2913539T3/es active Active
- 2013-03-28 CA CA2883890A patent/CA2883890C/en active Active
- 2013-03-28 CN CN201380047272.0A patent/CN104620111B/zh active Active
-
2015
- 2015-03-11 US US14/644,695 patent/US20150185230A1/en not_active Abandoned
-
2017
- 2017-11-16 JP JP2017220660A patent/JP6615848B2/ja active Active
-
2018
- 2018-03-05 US US15/911,699 patent/US11454634B2/en active Active
-
2022
- 2022-08-19 US US17/891,458 patent/US20220412991A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015531873A5 (enExample) | ||
| Winau et al. | High-sensitive troponin is associated with subclinical imaging biosignature of inflammatory cardiovascular involvement in systemic lupus erythematosus | |
| Imran et al. | Native T1 mapping in the diagnosis of cardiac allograft rejection: a prospective histologically validated study | |
| Carrick et al. | Prognostic significance of infarct core pathology revealed by quantitative non-contrast in comparison with contrast cardiac magnetic resonance imaging in reperfused ST-elevation myocardial infarction survivors | |
| Klok et al. | External validation of a simple non-invasive algorithm to rule out chronic thromboembolic pulmonary hypertension after acute pulmonary embolism | |
| Andruchow et al. | Contemporary emergency department management of patients with chest pain: a concise review and guide for the high-sensitivity troponin era | |
| Rusconi et al. | Serial measurements of serum NT-proBNP as markers of left ventricular systolic function and remodeling in children with heart failure | |
| Pugnet et al. | Cardiac involvement in granulomatosis with polyangiitis: a magnetic resonance imaging study of 31 consecutive patients | |
| Jing et al. | Ambulatory systolic blood pressure and obesity are independently associated with left ventricular hypertrophic remodeling in children | |
| Ray et al. | Pulmonary arterial stiffness assessed by cardiovascular magnetic resonance imaging is a predictor of mild pulmonary arterial hypertension | |
| Mayr et al. | Evaluation of myocardial involvement in patients with connective tissue disorders: a multi-parametric cardiovascular magnetic resonance study | |
| McComb et al. | Assessment of the relationships between myocardial contractility and infarct tissue revealed by serial magnetic resonance imaging in patients with acute myocardial infarction | |
| JP2015504519A5 (enExample) | ||
| Kobayashi et al. | Urinary 8-hydroxy-2′-deoxyguanosine as a novel biomarker of inflammatory activity in patients with cardiac sarcoidosis | |
| CN109891243A (zh) | 心房纤颤和中风的评价中的循环esm-1 (endocan) | |
| Ross et al. | Are troponin and B-type natriuretic peptides useful biomarkers for the diagnosis of systemic sclerosis heart involvement? A systematic literature review | |
| JP5847221B2 (ja) | アルツハイマー病罹患リスクを検出する方法 | |
| Deraz et al. | Assessment of ventricular dysfunction in Egyptian children with Beta-thalassemia major | |
| Schaaf et al. | Which high-sensitivity troponin variable best characterizes infarct size and microvascular obstruction? | |
| Yamasaki et al. | Clinical impact of left ventricular eccentricity index using cardiac MRI in assessment of right ventricular hemodynamics and myocardial fibrosis in congenital heart disease | |
| Abe et al. | Right ventricular dimension index by cardiac magnetic resonance for prognostication in connective tissue diseases and pulmonary hypertension | |
| Fairley et al. | Prognostic and functional importance of both overt and subclinical left ventricular systolic dysfunction in systemic sclerosis | |
| Casals et al. | Impact of ultrasensitive cardiac troponin I dynamic changes in the new universal definition of myocardial infarction | |
| Hanneman et al. | Cardiovascular CT in the diagnosis of pericardial constriction: predictive value of inferior vena cava cross-sectional area | |
| Liu et al. | A prospective study examining the role of myocardial F ibrosis in outcome following mitral valve repair IN DE generative mitral R egurgitation: rationale and design of the mitral FINDER study |